These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 31502248)

  • 1. Development Times and Approval Success Rates for Drugs to Treat Infectious Diseases.
    DiMasi JA; Florez MI; Stergiopoulos S; Peña Y; Smith Z; Wilkinson M; Getz KA
    Clin Pharmacol Ther; 2020 Feb; 107(2):324-332. PubMed ID: 31502248
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fixed-Dose Combination Drug Approvals, Patents and Market Exclusivities Compared to Single Active Ingredient Pharmaceuticals.
    Hao J; Rodriguez-Monguio R; Seoane-Vazquez E
    PLoS One; 2015; 10(10):e0140708. PubMed ID: 26469277
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Pharmaceutical Industry in 2019. An Analysis of FDA Drug Approvals from the Perspective of Molecules.
    de la Torre BG; Albericio F
    Molecules; 2020 Feb; 25(3):. PubMed ID: 32050446
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical approval success rates for investigational cancer drugs.
    DiMasi JA; Reichert JM; Feldman L; Malins A
    Clin Pharmacol Ther; 2013 Sep; 94(3):329-35. PubMed ID: 23739536
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Timing of pivotal clinical trial results reporting for newly approved medications varied by reporting source.
    Withycombe B; Ovenell M; Meeker A; Ahmed SM; Hartung DM
    J Clin Epidemiol; 2016 Sep; 77():78-83. PubMed ID: 27108488
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A 25-Year Experience of US Food and Drug Administration Accelerated Approval of Malignant Hematology and Oncology Drugs and Biologics: A Review.
    Beaver JA; Howie LJ; Pelosof L; Kim T; Liu J; Goldberg KB; Sridhara R; Blumenthal GM; Farrell AT; Keegan P; Pazdur R; Kluetz PG
    JAMA Oncol; 2018 Jun; 4(6):849-856. PubMed ID: 29494733
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characteristics of Trials Associated With Drugs Approved by the Food and Drug Administration in 2015 and 2016.
    Eckert JC
    Med Care; 2020 Mar; 58(3):194-198. PubMed ID: 32106163
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Availability of Investigational Medicines Through the US Food and Drug Administration's Expanded Access and Compassionate Use Programs.
    Puthumana J; Miller JE; Kim J; Ross JS
    JAMA Netw Open; 2018 Jun; 1(2):e180283. PubMed ID: 30646072
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Comparative Effectiveness of Innovative Treatments for Cancer (CEIT-Cancer) project: Rationale and design of the database and the collection of evidence available at approval of novel drugs.
    Ladanie A; Speich B; Naudet F; Agarwal A; Pereira TV; Sclafani F; Martin-Liberal J; Schmid T; Ewald H; Ioannidis JPA; Bucher HC; Kasenda B; Hemkens LG
    Trials; 2018 Sep; 19(1):505. PubMed ID: 30231912
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Exploratory analyses of efficacy data from major depressive disorder trials submitted to the US Food and Drug Administration in support of new drug applications.
    Khin NA; Chen YF; Yang Y; Yang P; Laughren TP
    J Clin Psychiatry; 2011 Apr; 72(4):464-72. PubMed ID: 21527123
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The drug lag issue: a 20-year review of China.
    Li X; Yang Y
    Invest New Drugs; 2021 Oct; 39(5):1389-1398. PubMed ID: 33928468
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antibiotic resistance: An infectious arms race.
    Hede K
    Nature; 2014 May; 509(7498):S2-3. PubMed ID: 24784426
    [No Abstract]   [Full Text] [Related]  

  • 13. The FDA Breakthrough-Drug Designation - Four Years of Experience.
    Darrow JJ; Avorn J; Kesselheim AS
    N Engl J Med; 2018 Apr; 378(15):1444-1453. PubMed ID: 29641970
    [No Abstract]   [Full Text] [Related]  

  • 14. New FDA breakthrough-drug category--implications for patients.
    Darrow JJ; Avorn J; Kesselheim AS
    N Engl J Med; 2014 Mar; 370(13):1252-8. PubMed ID: 24670173
    [No Abstract]   [Full Text] [Related]  

  • 15. Gender and Ethnicity of Enrolled Participants in U.S. Food and Drug Administration (FDA) Clinical Trials for Approved Ophthalmological New Molecular Entities.
    Birnbaum FA
    J Natl Med Assoc; 2018 Oct; 110(5):473-479. PubMed ID: 30129511
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 2014 in review: FDA approval of new drugs.
    Kinch MS
    Drug Discov Today; 2017 Apr; 22(4):620-624. PubMed ID: 26100738
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Statistical considerations for rare diseases drug development.
    Chow SC; Chang YW
    J Biopharm Stat; 2019; 29(5):874-886. PubMed ID: 31454299
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Innovating by developing new uses of already-approved drugs: trends in the marketing approval of supplemental indications.
    DiMasi JA
    Clin Ther; 2013 Jun; 35(6):808-18. PubMed ID: 23726388
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Availability of comparative efficacy data at the time of drug approval in the United States.
    Goldberg NH; Schneeweiss S; Kowal MK; Gagne JJ
    JAMA; 2011 May; 305(17):1786-9. PubMed ID: 21540422
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Key Findings from Preclinical and Clinical Drug Interaction Studies Presented in New Drug and Biological License Applications Approved by the Food and Drug Administration in 2014.
    Yu J; Ritchie TK; Zhou Z; Ragueneau-Majlessi I
    Drug Metab Dispos; 2016 Jan; 44(1):83-101. PubMed ID: 26424199
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.